ANIP

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -1.50
Percentage change -2.37	%

Peers: AMGN REGN VRTX BIIB GILD ILMN BMRN INCY NBIX UTHR

| Held by: IJR VTI IWM VXF IJT SPSM PJP IWO SLYG SCHA

Index	RUT	P/E	-	EPS (ttm)	-1.13	Insider Own	18.75%	Shs Outstand	21.11M	Perf Week	1.16%
Market Cap	1.34B	Forward P/E	9.05	EPS next Y	6.82	Insider Trans	-1.39%	Shs Float	17.69M	Perf Month	3.19%
Income	-21.95M	PEG	-	EPS next Q	1.34	Inst Own	90.57%	Short Float	14.44%	Perf Quarter	6.43%
Sales	614.38M	P/S	2.19	EPS this Y	21.32%	Inst Trans	-0.08%	Short Ratio	10.04	Perf Half Y	11.32%
Book/sh	19.11	P/B	3.23	EPS next Y	8.13%	ROA	-1.86%	Short Interest	2.56M	Perf Year	-6.61%
Cash/sh	6.94	P/C	8.89	EPS next 5Y	14.00%	ROE	-4.86%	52W Range	52.50 - 70.81	Perf YTD	11.72%
Dividend Est.	-	P/FCF	28.14	EPS past 5Y	-	ROI	-2.09%	52W High	-12.78%	Beta	0.52
Dividend TTM	-	Quick Ratio	2.02	Sales past 5Y	36.29%	Gross Margin	48.25%	52W Low	17.64%	ATR (14)	2.62
Dividend Ex-Date	-	Current Ratio	2.72	EPS Y/Y TTM	-219.22%	Oper. Margin	0.36%	RSI (14)	56.73	Volatility	5.16% 4.29%
Employees	897	Debt/Eq	1.62	Sales Y/Y TTM	26.20%	Profit Margin	-3.57%	Recom	1.43	Target Price	81.71
Option/Short	Yes / Yes	LT Debt/Eq	1.60	EPS Q/Q	-1508.46%	Payout	0.00%	Rel Volume	0.32	Prev Close	63.26
Sales Surprise	8.68%	EPS Surprise	13.59%	Sales Q/Q	44.75%	Earnings	Feb 28 BMO	Avg Volume	254.42K	Price	61.76
SMA20	4.66%	SMA50	6.25%	SMA200	3.78%	Trades		Volume	53,231	Change	-2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-25	Initiated	JP Morgan	Overweight	$85
Dec-11-24	Initiated	Leerink Partners	Outperform	$80
Oct-11-24	Initiated	Piper Sandler	Overweight	$68
Mar-15-24	Initiated	CapitalOne	Overweight	$80
Aug-22-23	Reiterated	H.C. Wainwright	Buy	$60 → $73
Mar-01-23	Initiated	Guggenheim	Buy	$55
Sep-07-22	Initiated	H.C. Wainwright	Buy	$50
Nov-02-21	Initiated	Truist	Buy	$70
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform	$73 → $82
Oct-16-17	Reiterated	Canaccord Genuity	Buy	$60 → $66
Jul-31-17	Initiated	Canaccord Genuity	Buy	$60
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy	$68
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy	$54
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy	$67 → $60
Aug-05-15	Reiterated	Oppenheimer	Outperform	$74 → $65
Aug-04-15	Reiterated	ROTH Capital	Neutral	$70 → $67

Show Previous Ratings

Today 05:01AM	Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Mar-12-25 08:56AM	1 Growth Stock to Target This Week and 2 to Avoid (StockStory)
Mar-07-25 09:55AM	Wall Street Analysts Believe ANI (ANIP) Could Rally 32.4%: Here's is How to Trade (Zacks)
Mar-06-25 12:45PM	ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:00PM	ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
09:40AM	Loading…
Mar-05-25 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
09:40AM	Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year? (Zacks)
04:03AM	Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers (StockStory)
Mar-03-25 04:30PM	ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel Prefilled Syringe (GlobeNewswire) -5.54%
Mar-01-25 04:57AM	Q4 2024 ANI Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	ANI Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-28-25 01:50PM	Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today (StockStory) +13.39%
09:30AM	ANI (ANIP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:11AM	ANI: Q4 Earnings Snapshot (Associated Press Finance)
06:54AM	ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars (StockStory)
06:50AM	Loading…
06:50AM	ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance (GlobeNewswire)
Feb-27-25 07:17AM	ANI Pharmaceuticals Inc (ANIP) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-21-25 04:07AM	Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Feb-19-25 04:30PM	ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March (GlobeNewswire)
04:01AM	Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest (StockStory)
Feb-18-25 04:05PM	ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET (GlobeNewswire)
Feb-17-25 09:40AM	Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? (Zacks)
09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
Feb-14-25 04:01AM	Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)
Feb-13-25 04:01AM	ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group (StockStory)
Jan-31-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now? (Zacks)
09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-28-25 04:30PM	ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference (GlobeNewswire)
Jan-15-25 09:40AM	Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? (Zacks)
Jan-13-25 11:12AM	Alcami Announces CEO Transition (PR Newswire)
06:50AM	Loading…
06:50AM	ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook (GlobeNewswire)
Jan-02-25 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity (GlobeNewswire)
Jan-01-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-30-24 04:05PM	ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 12:00PM	All You Need to Know About ANI (ANIP) Rating Upgrade to Buy (Zacks)
Dec-18-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Dec-02-24 02:21PM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Nov-26-24 04:30PM	ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
09:55AM	Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect? (Zacks)
Nov-20-24 12:00PM	ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-14-24 09:40AM	Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? (Zacks)
Nov-09-24 04:00AM	ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-08-24 10:00AM	Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics (Zacks) +5.24%
08:21AM	ANI Pharma Boosts FY24 Outlook As Q3 Results Top Estimates - Update (RTT News)
08:05AM	ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates (Zacks)
06:58AM	ANI: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance (GlobeNewswire)
Nov-07-24 07:06AM	ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-04-24 04:30PM	ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Nov-01-24 10:00AM	Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline (Zacks)
Oct-30-24 05:00PM	ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET (GlobeNewswire)
Oct-25-24 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% (GlobeNewswire)
Oct-24-24 06:50AM	ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-23-24 09:20AM	ANI Pharmaceuticals price target raised to $62 from $60 at Truist (TipRanks)
Oct-21-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Oct-15-24 12:10PM	Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-11-24 01:40PM	ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential (Benzinga)
Oct-09-24 09:55AM	Wall Street Analysts Predict a 42.98% Upside in ANI (ANIP): Here's What You Should Know (Zacks)
Sep-27-24 09:40AM	Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? (Zacks)
Sep-26-24 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% (GlobeNewswire)
Sep-16-24 08:53AM	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences (GlobeNewswire)
06:50AM	ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences (GlobeNewswire)
Sep-13-24 06:50AM	ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution (GlobeNewswire)
Sep-11-24 06:50AM	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger (Business Wire)
Sep-10-24 02:09PM	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences (GlobeNewswire) -5.13%
09:00AM	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement (Business Wire)
Aug-28-24 12:15PM	ANI Pharmaceuticals, Inc. (ANIP): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-15-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Aug-13-24 04:05PM	ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers' Option to Purchase Additional Notes (GlobeNewswire)
Aug-07-24 09:44PM	ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering (GlobeNewswire) -9.92%
07:00AM	ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
Aug-06-24 10:00AM	Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics (Zacks) +6.98%
08:05AM	ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates (Zacks)
06:58AM	ANI: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance (GlobeNewswire)
Aug-05-24 09:16AM	Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Jul-31-24 07:00AM	ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET (GlobeNewswire)
Jul-15-24 07:00AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder (GlobeNewswire)
Jul-02-24 07:00AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP (GlobeNewswire)
Jun-25-24 07:00AM	ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year 2024 New Jersey Award Winner (GlobeNewswire)
Jun-24-24 11:28AM	Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal (Benzinga) +7.33%
11:14AM	Alimera Sciences shares jump by 77% after being acquired by ANI (Pharmaceutical Technology)
06:50AM	ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences (GlobeNewswire)
Jun-13-24 08:53AM	Implied Volatility Surging for ANI Pharmaceuticals (ANIP) Stock Options (Zacks)
Jun-06-24 01:00PM	Insider Sale: SVP & CFO Stephen Carey Sells 5,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-29-24 04:30PM	ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-24 10:52AM	ANI Pharmaceuticals Launches Kionex Suspension (MT Newswires)
09:35AM	Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround (Zacks)
06:50AM	ANI Pharmaceuticals Announces the Launch of Kionex Suspension (GlobeNewswire)
May-18-24 02:33AM	Director Renee Tannenbaum Sells 2,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-16-24 07:00PM	Insider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
05:08PM	Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing (MT Newswires)
May-13-24 03:03AM	ANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 01:48PM	ANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue Expectations (GuruFocus.com)
11:54AM	ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	ANI (ANIP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:26AM	ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance (MT Newswires)
06:58AM	ANI: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davis Krista	SVP, CHIEF HR OFFICER	Mar 07 '25	Sale	60.86	1,000	60,860	66,525	Mar 10 08:28 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Option Exercise	31.49	300	9,447	99,476	Mar 07 04:09 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Sale	60.00	5,384	323,049	94,092	Mar 07 04:09 PM
Davis Krista	SVP, CHIEF HR OFFICER	Feb 21 '25	Sale	60.20	1,000	60,200	68,624	Feb 24 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '25	Sale	59.54	400	23,816	83,478	Feb 18 08:12 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 13 '25	Sale	53.92	400	21,568	55,588	Jan 13 04:15 PM
CAREY STEPHEN P.	SVP & CFO	Dec 17 '24	Sale	55.79	7,500	418,425	154,468	Dec 18 05:59 PM
CAREY STEPHEN P.	Officer	Dec 17 '24	Proposed Sale	55.25	7,500	414,375		Dec 17 05:35 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Dec 13 '24	Sale	56.24	250	14,060	55,988	Dec 16 04:20 PM
Davis Krista	SVP, CHIEF HR OFFICER	Dec 11 '24	Sale	60.00	1,000	60,000	49,059	Dec 12 05:08 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Option Exercise	29.00	30,000	870,000	403,859	Nov 27 05:38 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Sale	57.99	33,481	1,941,442	370,378	Nov 27 05:38 PM
Lalwani Nikhil	Officer	Nov 26 '24	Proposed Sale	57.99	33,481	1,941,484		Nov 26 07:44 PM
Mutz Christopher	HEAD OF RARE DISEASE	Nov 15 '24	Sale	57.70	6,500	375,050	76,777	Nov 18 04:03 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Nov 13 '24	Sale	61.36	250	15,340	56,238	Nov 14 04:16 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Oct 14 '24	Sale	57.19	250	14,298	56,488	Oct 15 05:57 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 13 '24	Sale	56.82	250	14,205	56,738	Sep 16 04:50 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '24	Sale	59.62	250	14,905	56,988	Aug 14 08:29 AM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 18 '24	Sale	62.00	2,743	170,066	632,620	Jul 19 05:30 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 16 '24	Sale	64.27	22,000	1,413,940	649,620	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 17 '24	Sale	63.16	14,257	900,472	635,363	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 15 '24	Sale	63.38	11,000	697,180	671,620	Jul 17 07:07 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 12 '24	Sale	64.91	250	16,228	58,981	Jul 15 04:38 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jul 01 '24	Sale	63.44	20,000	1,268,800	193,226	Jul 02 08:58 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 21 '24	Sale	58.90	20,000	1,178,000	682,620	Jun 24 04:12 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 20 '24	Sale	59.86	11,447	685,217	702,620	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 18 '24	Sale	60.76	10,607	644,481	714,067	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 17 '24	Sale	61.41	7,946	487,964	724,674	Jun 20 07:11 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 13 '24	Sale	63.80	250	15,950	59,231	Jun 14 05:23 PM
Marken James G.	SVP OPS & PROD DEV	Jun 07 '24	Option Exercise	52.70	12,550	661,366	128,916	Jun 11 04:51 PM
Gutwerg Ori	SVP, GENERICS	Jun 05 '24	Sale	67.00	2,985	199,995	77,227	Jun 06 06:21 PM
CAREY STEPHEN P.	SVP & CFO	Jun 04 '24	Sale	63.58	5,000	317,900	161,968	Jun 06 07:34 AM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jun 03 '24	Sale	64.41	20,000	1,288,200	213,226	Jun 04 06:08 PM
Mutz Christopher	HEAD OF RARE DISEASE	May 21 '24	Sale	61.61	2,000	123,220	83,277	May 22 06:14 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 20 '24	Sale	61.81	12,855	794,568	732,620	May 21 05:21 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 16 '24	Sale	63.84	16,459	1,050,743	751,311	May 17 06:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 15 '24	Sale	65.86	14,850	978,021	767,770	May 17 06:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 17 '24	Sale	62.09	5,836	362,357	745,475	May 17 06:05 PM
TANNENBAUM RENEE P	Director	May 16 '24	Sale	63.87	2,000	127,740	18,211	May 17 06:01 PM
Lalwani Nikhil	PRESIDENT & CEO	May 14 '24	Sale	66.10	16,669	1,101,821	377,505	May 16 05:02 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '24	Sale	67.69	250	16,922	59,481	May 13 05:25 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	May 01 '24	Sale	66.62	20,000	1,332,400	233,226	May 03 05:48 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 19 '24	Sale	65.17	16,809	1,095,443	782,620	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 18 '24	Sale	64.98	10,423	677,287	799,429	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 17 '24	Sale	65.40	9,520	622,608	809,852	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 15 '24	Sale	66.33	7,414	491,771	825,206	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 16 '24	Sale	66.20	5,834	386,211	819,372	Apr 17 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 12 '24	Sale	67.79	250	16,948	59,731	Apr 15 06:28 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Apr 01 '24	Sale	67.25	20,000	1,345,000	253,226	Apr 02 06:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANI Pharmaceuticals Inc

Upgrade your FINVIZ experience